| The Medicines Company announced the data from 13,941 patients treated in the discontinued CHAMPION Phase III program of cangrelor. While cangrelor did not show superiority to 600 mg clopidogrel given orally for the pre-specified primary endpoint comprising death, MI, or ischemia driven revascularization, IDR, at 48 hours, full analysis of the CHAMPION program data revealed strong evidence of pharmacological effects, clinical effectiveness and suitable safety in patients undergoing percutaneous coronary intervention,PCI. In fact, cangrelor significantly reduced the composite endpoint of death, Q-wave myocardial infarction,MI, and IDR. :theflyonthewall.com |
